Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Healius Limited
  6. Summary
    HLS   AU0000033359

HEALIUS LIMITED

(HLS)
  Report
Delayed Australian Stock Exchange  -  02:10:14 2023-06-02 am EDT
3.090 AUD   -0.64%
05/10Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023
CI
05/02Nexus Day Hospitals Pty Ltd completed the acquisition of Montserrat Healthcare Pty Ltd from Healius Limited for AUD 140 million.
CI
03/30Morgan Stanley Infrastructure Partners to Bid Rival Offer for Healius
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Australian Stock Exchange
05/29/2023 05/30/2023 05/31/2023 06/01/2023 06/02/2023 Date
3.14(c) 3.12(c) 3.16(c) 3.11(c) 3.09 Last
1 740 680 844 205 3 010 752 954 379 904 151 Volume
+1.95% -0.64% +1.28% -1.58% -0.64% Change
More quotes
Estimated financial data (e)
Sales 2023 1 737 M 1 141 M 1 141 M
Net income 2023 8,76 M 5,75 M 5,75 M
Net Debt 2023 1 616 M 1 062 M 1 062 M
P/E ratio 2023 111x
Yield 2023 0,70%
Sales 2024 1 797 M 1 180 M 1 180 M
Net income 2024 67,2 M 44,1 M 44,1 M
Net Debt 2024 1 533 M 1 007 M 1 007 M
P/E ratio 2024 25,8x
Yield 2024 2,29%
Capitalization 1 771 M 1 163 M 1 163 M
EV / Sales 2023 1,95x
EV / Sales 2024 1,84x
Nbr of Employees 11 000
Free-Float 98,9%
More Financials
Company
Healius Limited is an Australia-based healthcare company. The Company operates through two segments: Pathology, and Imaging. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment is a provider of imaging and scanning services at standalone imaging sites, hospitals, and medical centers. The Company has a network of pathology laboratories,... 
Read more
More about the company
Ratings of Healius Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about HEALIUS LIMITED
05/10Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective..
CI
05/02Nexus Day Hospitals Pty Ltd completed the acquisition of Montserrat Healthcare Pty Ltd ..
CI
03/30Morgan Stanley Infrastructure Partners to Bid Rival Offer for Healius
CI
03/28Healius Limited Announces Change in Company Secretary
CI
03/27Australia's Downer appoints new finance chief amid regulatory woes
RE
03/20Australian Clinical Labs Reportedly Taps Goldman Sachs as it Bids for Healius
CI
03/20Healius Limited Appoints Charlie Taylor as Non-Executive Director
CI
03/20Healius Limited Appoints Stephen Humphries as Company Secretary
CI
03/20No Enthusiasm To Combine ACL & Healius
AQ
03/20Correction: Australian Clinical Labs Makes AU$1.5 Billion Takeover Offer for ..
MT
03/20Banking Crisis Fears Drag Australian Shares to Over Four-Month Low
MT
03/20Australian Clinical Labs Limited (ASX:ACL) expresse..
CI
03/19Australian Clinical Labs Makes AU$1.5 Billion Takeover Offer for Healius; Shares Rise
MT
03/19Financials drag Australian shares on banking crisis worries
RE
03/19Australian Clinical Labs offers to buy Healius for $1 bln
RE
More news
News in other languages on HEALIUS LIMITED
05/10Healius Limited nomme Jan Van Rooyen au poste de directeur de groupe, Healius Pathology..
05/02Nexus Day Hospitals Pty Ltd a finalisé l'acquisitio..
03/30Morgan Stanley Infrastructure Partners propose une offre concurrente pour Healius
03/28Healius Limited annonce un changement de secrétaire général
03/20Australian Clinical Labs aurait fait appel à Goldman Sachs pour son offre d'achat sur H..
More news
ETFs positioned on HEALIUS LIMITEDETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
SPDR MSCI Australia Select High Dividend Yi...1.83%-1.34%-Australia
Global X S&P/ASX 300 High Yield Plus ETF - AUD1.59%-2.45%-Australia
VanEck Small Companies Masters ETF - AUD1.55%0.22%-Australia
SPDR S&P/ASX Small Ordinaries Fund ETF - AUD0.77%0.08%-Australia
IShares S&P/ASX Small Ordinaries ETF - AUD0.76%-0.23%-Australia
More ETFs positioned on HEALIUS LIMITED
Chart HEALIUS LIMITED
Duration : Period :
Healius Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HEALIUS LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 3,11 AUD
Average target price 3,13 AUD
Spread / Average Target 0,59%
EPS Revisions
Managers and Directors
Maxine Jaquet Chief Executive Officer, MD & Director
Paul Anderson Group Chief Financial Officer
Jennifer Mitchell Macdonald Chairman
Prasad Arav Group Executive-Digital & Technology
Gordon R. Davis Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HEALIUS LIMITED1.30%1 163
SONIC HEALTHCARE LIMITED18.25%10 942
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.-7.93%4 741
NEOGENOMICS, INC.91.02%2 252
SYNLAB AG-21.00%2 134
DR. LAL PATHLABS LIMITED-11.29%2 017
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer